分组1 - Exact Sciences reported a quarterly loss of $0.27 per share, better than the Zacks Consensus Estimate of a loss of $0.53, and improved from a loss of $0.72 per share a year ago, representing an earnings surprise of 49.06% [1] - The company achieved revenues of $646.89 million for the quarter ended December 2023, exceeding the Zacks Consensus Estimate by 2.36% and up from $553 million in the same quarter last year [1] - Exact Sciences has surpassed consensus EPS estimates and revenue estimates in each of the last four quarters [1] 分组2 - The stock has underperformed, losing about 15.2% since the beginning of the year compared to the S&P 500's gain of 4.3% [2] - The future performance of Exact Sciences' stock will depend on management's commentary during the earnings call and the company's earnings outlook [2] - Current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $656.92 million, and for the current fiscal year, it is -$1.15 on revenues of $2.82 billion [4] 分组3 - The Medical - Biomedical and Genetics industry, to which Exact Sciences belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [4] - The Zacks Rank for Exact Sciences is 1 (Strong Buy), suggesting that the stock is expected to outperform the market in the near future [3]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 _____________________________________________________________________________ ...

Exact Sciences (EXAS) is slated to report its fourth-quarter and full-year 2023 earnings on Feb 21.Exact Sciences is a leading cancer diagnostics company, which focuses on the development of new and innovative tests for the prevention of cancer through early detection. The company’s portfolio of FDA-approved flagship cancer screening and diagnostics tests includes Cologuard and Oncotype DX.Let us see how things have shaped up for the quarter to be reported.Factors to ConsiderExact Sciences reports its reven ...

The market expects Exact Sciences (EXAS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rel ...

Company Announcements - Exact Sciences Corp plans to release its fourth quarter 2023 financial results after the close of the US financial markets on February 21 2024 [1] - The company will host a webcast and conference call at 5 pm ET on February 21 2024 to discuss financial results and business progress [1] - The live webcast can be accessed at www exactsciences com and a replay will be available on the same website [1] - Domestic callers can dial 888-330-2384 and international callers can dial +1 240-789-2701 with access code 4437608 for both [1] Company Overview - Exact Sciences Corp is a leading provider of cancer screening and diagnostic tests [2] - The company focuses on providing clarity to patients and healthcare professionals for early life-changing actions [2] - Exact Sciences is building on the success of its Cologuard® and Oncotype® tests [2] - The company is investing in its pipeline to develop innovative solutions for use before during and after a cancer diagnosis [2]

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.The earnings figure itself is key, of course, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb and vice versa.The ability to identify stocks that are likely to ...

Company Overview - Exact Sciences Co. specializes in FDA-approved cancer screening and diagnostic tests, with Cologuard being its leading product for colorectal cancer detection [3] - The company has a diverse portfolio of cancer tests, including Oncotype DX for breast cancer, CancerSEEK for early detection of multiple cancers, and Oncoguard Liver for liver cancer [4] Pipeline and Development - Exact Sciences is developing Cancerguard, a test for early-stage cancer detection, and the next-gen Cologuard, which is undergoing a large clinical trial with over 20,000 participants [5] - The company is also working on a colorectal cancer blood test aimed at 44 million Americans needing screening [5] Financial Performance - For Q3 2023, Exact Sciences reported breakeven EPS, beating analyst estimates by 47 cents, and revenues increased by 20.1% to $628.34 million, surpassing the consensus estimate of $616.79 million [6] - The company raised its full-year 2023 revenue guidance to between $2.476 billion and $2.486 billion, exceeding the previous consensus estimate of $2.46 billion [6] Future Guidance - On January 8, 2024, Exact Sciences provided an upside Q4 2023 revenue guidance of $645.5 million to $647.5 million, reflecting a 17% year-over-year increase, compared to the consensus estimate of $631.48 million [6] - The company anticipates full-year 2023 revenues to align with consensus estimates at $2.83 billion [6] Competitor Analysis - Hologic reported Q4 2023 EPS of 89 cents, with a 5.5% year-over-year revenue decline to $945.3 million, although organic revenue growth was 17.5% excluding COVID-related revenues [9] - Amicus Therapeutics reported a 26.7% revenue increase to $103.5 million for Q3 2023, raising its full-year revenue guidance for Galafold to 16% to 18% growth [13][14]

Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits next-generation Cologuard® to FDA Announces Chief Financial Officer succession plan Highlighted announcements: Expects total fourth quarter revenue of $645.5-$647.5 million, an increase of 17% compared to the fourth quarter of 2022, with Screening revenue of $486.0-$487.0 million and Precision Oncology revenue of $159.5-$160.5 million Expects total full-year 2023 revenue of $2.50 billion and 2024 revenue of ...

MADISON, Wis., Jan. 2, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San FranciscoPresentation followed by Q&A on Monday, January 8, 2024 at 2:15 p.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. ...

We aim to help eradicate cancer by preventing it, detecting it earlier, and guiding its treatment. Third-quarter 2023 earnings call November 1, 2023 EXACT SCIENCES 1 Safe harbor and non-GAAP disclosures This pre ...